Tariffs on active pharmaceutical ingredients (APIs) imported into the US from China must be cut from a package of measures proposed by the US Trade Representative (USTR), to avoid drug shortages, higher costs and firms dropping out of the generics market, according to the US Association for Accessible Medicines (AAM).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?